Information Provided By:
Fly News Breaks for June 11, 2018
TSRO
Jun 11, 2018 | 07:51 EDT
Oppenheimer analyst Leah Rush Cann lowered her price target for Tesaro to $83 from $122 saying that she believes the current status of the PARP inhibitor market is resulting in less predictable physician adoption than is typical in oncology settings. The analyst is adjusting her 2018-2022 outlook for Tesaro to account for lower estimated Zejula sales.Cann reiterates an Outperform rating on the shares.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.